Optimization of combination chemotherapy based on the calculation of network entropy for protein-protein interactions in breast cancer cell lines

EPJ Nonlinear Biomedical Physics

Table 4 Expected benefit of drug combination in breast cancer therapy using entropy data from Additional file 2: Table S2 and the relationship y = −0.0005*x + 11.4732

	Targets	Drug combination	Benefit, %
BT-20			157
P00533	EGFR	Gefitinib, erlotinib, cetuximab, lapatinib, panitumumab, vandetanib, trastuzumab, pertuzumab, afatinib, neratinib, AZD9291, CLO-1686^a [15]	120
P62258	YWHAE	Fusicoccin^c [16]	91
MDA-MB-231			157
P31946	YWHAB	Difopein^b [17], R18^c [18]	127
P62258	YWHAE	Fusicoccin^c [16]	104
MDA-MB-468			229
P00533	EGFR	Gefitinib, erlotinib, cetuximab, lapatinib, panitumumab, vandetanib, trastuzumab, pertuzumab, afatinib, neratinib, AZD9291, CLO-1686^a [15]	146
P31946	YWHAB	Difopein^b [17], R18^c [18]	140
P62258	YWHAE	Fusicoccin^c [16]	116
MCF-7			216
P62993	GRB2	CGP78850^c [19], C90^b [20]	195
P06748	NPM1	NSC348884^c [21]	111
T-47D			105
P62258	YWHAE	Fusicoccin^c [16]
ZR-75-1			236
P62993	GRB2	CGP78850^c [19], C90^b [20]	162
P62258	YWHAE	Fusicoccin^c [16]	89
P51858	HDGF	HDGF-H3^b [22]	81
P06748	NPM1	NSC348884^c [21]	79
BT-474			214
P31946	YWHAB	Difopein^b [17], R18^c [18]	151
P04626	ERBB2	Trastuzumab, pertuzumab, NeuVax vaccine^a [23]	130
P62258	YWHAE	Fusicoccin^c [16]	127